Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui Pharmaceuticals’ investigational cardiovascular disease (CVD) drug in a ...

Under the latest deal, announced on Tuesday, Merck will get exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals' experimental oral heart disease drug, HRS-5346, worldwide ...

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug, HRS-5346. Hengrui Pharma will ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals ... Novo Nordisk is paying $200 million upfront to United Laboratories for obesity drug UBT251. Bayer ...

including 64 million people in the U.S. Merck buys rights to heart disease drug in latest China deal Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui ...

Rather, it brings with it platform capabilities in formulations of mRNA drugs ... disease applications including heart failure. "The acquisition of Exelead will further enable Merck to capture ...

a deal that could give it access to a recently approved rare disease drug and expand its portfolio of experimental cancer treatments. Merck said that the companies are in discussions on the basis ...